Provenance Biopharmaceuticals (Waltham, MA) a clinical-stage biopharmaceutical company focused on monoclonal antibody therapy for non-Hodgkins lymphoma and other hematological cancers, closed a $8M Series A financing. Participants include Alopexx Enterprises.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.
The 2Q11 OnBioVC Trend Analysis will be [...]

Anergis (Switzerland) a clinical-stage biopharmaceutical company focused on immunotherapies against allergies, closed announced today that it has closed a $14.3M Series A financing. Participants include Vinci Capital, BioMedInvest, Sunstone Capital, Esperante Ventures and Initiative Capital Romandie.

DBV Technologies (France) a clinical-stage drug:device biopharma company focused on non invasive immunotherapy delivery for food allergies, closed a $25.5M Series C financing. Participants include InnoBio Fund, Lundbeckfond Ventures, ALTO Invest, Sofinnova Partners, ALK Abello and Apax Partners.

Vaximm (Switzerland) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for various solid tumors, closed a $8M Series B financing. Participants include BB Biotech Ventures, Sunstone Capital, Merck Serono Ventures and BioMedPartners.

Kite Pharma (Los Angeles, CA) a preclinical-stage biopharmaceutical company focused on therapeutic vaccines for renal cell carcinoma and hepatocellular carcinoma, closed a $15M Series A financing. Participants include TPG Capital.

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on monoclonal antibodies for the treatment of inflammation and immune related disorders, closed a $20.8M Series B financing. Participants include BZ Bank Aktiengesellschaft.

Helix Therapeutics (New Haven, CT) a preclinical-stage company developing triplex-forming oligonucleotides to target genome modification with a focused on hemoglobin, immune and lysosomal storage disorders, closed a $2.5M Series A financing. Participants include Canaan Partners and Connecticut Innovations.

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on immune, metabolic and hematologic indications, closed a $23M Series C financing. Participants include Domain Associates, Alta Partners, Cardinal Partners and Polaris Ventures.

Immatics Biotechnologies (Germany) a clinical-stage biotechnology company focused on therapeutic vaccines against renal and colorectal cancers, closed a $71M Series C financing. Participants include dievini Hopp Biotech, Wellington Partners and MIG Verwaltungs.

Immune Targeting Systems (United Kingdom) a clinical-stage biopharma focused on synthetic vaccines for seasonal influenza strains, closed a $13.2M Series A financing, bringing the total round to $20.2M. Participants include Novartis Venture Funds, HealthCap, Truffle Capital and London Technology Fund.

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb